ZLAB — Zai Lab Ltd

Nasdaq · Health Care · Pharmaceuticals · CIK 1704292 · China
Last close
$17.07
Market Cap
$1.92B
52W High
$25.28
52W Low
$16.26
ADV30
905,810
Next earnings
2026-08-06
Zai Lab Limited, a biopharmaceutical company, focuses on discovering, developing, and commercializing products that address medical conditions in the areas of oncology, immunology, neuroscience, and infectious diseases. Its commercial products include Zejula, an orally administered poly (ADP-ribose) polymerase 1/2 inhibitor for treating ovarian cancer; VYVGART, a human IgG1 antibody fragment for generalized myasthenia gravis and chronic inflammatory demyelinating polyneuropathy; NUZYRA for community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections; Optune for glioblastoma multiforme; Qinlock for gastrointestinal stromal tumors; Xacduro for treating hospital-acquired and ventilator-associated bacterial pneumonia caused by a cinetobacter baumannii-calcoaceticus complex; and Augtyro for the treatment of ROS proto-oncogene 1 and non-small cell lung cancer. The company has a strategic collaboration with Tesaro, Inc., NovoCure Ltd., Deciphera Pharmaceuticals, LLC, Paratek Bermuda Ltd., argent BV, Turning Point Therapeutics, Inc., Entasis Therapeutics Holdings Inc., Karuna Therapeutics, Inc., Pfizer Inc., Amgen Inc., and with Boehringer Ingelheim GmbH. The company was incorporated in 2013 and is based in Pudong, China.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGrossProfit OpIncomeNetIncomeAssets CashLiabilities
Mar 2026 99,611,000 61,276,000 -69,279,000 -51,016,000 1,095,737,000 651,316,000 433,756,000
Dec 2025 127,597,000 65,266,000 -68,264,000 -50,409,000 1,172,384,000 679,573,000 456,884,000
Sep 2025 116,095,000 69,212,000 -47,968,000 -35,963,000 1,158,940,000 717,155,000 398,995,000
Jun 2025 109,977,000 66,757,000 -51,045,000 -40,727,000 1,164,101,000 732,159,000 372,366,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-101,002,000
Investing CF
$-40,555,000
Financing CF
$34,785,000
CapEx
$-31,847,000
Dividends Paid
Buybacks
EPS Diluted TTM
$-1.70
As of
2026-05-10

Balance + Analyst (yfinance extras)

Retained Earnings
$-2,679,636,000
Inventory
$85,961,000
Receivables
$61,998,000
ST Investments
$10,000,000
EBIT TTM
$-173,942,000
Pretax Income TTM
$-179,602,000
Interest Exp TTM
$5,660,000
Analysts
12

Yahoo Snapshot (yfinance, live)

Total Revenue
$453,280,000
EBITDA
$-227,012,000
Free Cash Flow
$-73,355,376
Enterprise Value
$1,488,490,368
Total Cash
$661,315,968
Total Debt
$231,908,992
Shares Out
112,354,858
Trailing EPS
$-1.70
Book Value
$6.47
ROE
-24.2%
ROA
-13.4%
Div Yield

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOpIncome NetIncomeAssetsLiabilities EquityOCF
Dec 2025 460,156,000 -223,572,000 -175,537,000 1,172,384,000 456,884,000 -150,789,000
Dec 2024 398,988,000 -273,947,000 -257,103,000 1,185,753,000 344,855,000 -214,869,000
Dec 2023 266,719,000 -374,140,000 -334,620,000 1,036,295,000 240,177,000 -198,178,000
Dec 2022 215,040,000 -392,886,000 -443,286,000 1,220,140,000 174,545,000 -367,642,000

TTM Snapshot

Revenues TTM
$102,265,000
NetIncome TTM
$-41,671,000
OpCashFlow TTM
$0
Assets (Latest)
$1,185,753,000
Forward EPS
$-1.75

Max Pain — expiry 2026-12-18

max pain strike: $25.00 · spot: $17.73 · call oi: 162 · put oi: 2,757
Expected Move to 2026-12-18: ±$6.07 (34.26%) — implied range $11.65$23.80 · ATM straddle on $17.50 strike

Peers — same industry

TickerNameMarket CapLastDaily %
BHC Bausch Health Companies Inc. $1.89B $5.06
HCM HUTCHMED (China) Ltd $1.88B $10.96
OCUL OCULAR THERAPEUTIX, INC $1.96B $8.94
STOK Stoke Therapeutics, Inc. $1.86B $29.82
HMDCF HUTCHMED (China) Ltd $1.86B $2.16

News headlines (Yahoo Finance, 1h cache)

Asian Equities Traded in the US as American Depositary Receipts Lower in Wednesday Trading
2026-06-10 14:36 · Yahoo
Zai Lab Receives China NMPA Approval of TIVDAK® (tisotumab vedotin for injection) for the Treatment of Adult Patients with Recurrent or Metastatic Cervical Cancer
2026-06-09 00:34 · Yahoo
Zai Lab (ZLAB) Is Down 6.0% After Leadership Shake-Up And 2026 Data Focus Has The Bull Case Changed?
2026-06-06 23:13 · Yahoo
Zai Lab (ZLAB) Announces Senior Leadership Changes
2026-06-05 21:03 · Yahoo
Asian Equities Traded in the US as American Depositary Receipts Decline in Friday Trading; Up for Week
2026-05-29 14:40 · Yahoo
Zai Lab Announces Changes to Senior Leadership Team
2026-05-21 22:09 · Yahoo
Asian Equities Traded in the US as American Depositary Receipts Lower in Monday Trading
2026-05-18 14:44 · Yahoo
Asian Equities Traded in the US as American Depositary Receipts Fall Sharply in Friday Trading
2026-05-15 14:38 · Yahoo
Asian Equities Traded in the US as American Depositary Receipts Open Week Lower in Monday Trading
2026-05-11 14:37 · Yahoo
Zai Lab Limited (NASDAQ:ZLAB) Analysts Are Cutting Their Estimates: Here's What You Need To Know
2026-05-11 13:58 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.